PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) Fundamental Analysis & Valuation

EPA:ALPAT • FR0010785790

Current stock price

7.9 EUR
+0.1 (+1.28%)
Last:

This ALPAT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ALPAT.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALPAT was profitable.
  • In multiple years ALPAT reported negative net income over the last 5 years.
  • In multiple years ALPAT reported negative operating cash flow during the last 5 years.
ALPAT.PA Yearly Net Income VS EBIT VS OCF VS FCFALPAT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M -2M

1.2 Ratios

  • ALPAT's Return On Assets of 2.04% is fine compared to the rest of the industry. ALPAT outperforms 72.15% of its industry peers.
  • ALPAT's Return On Equity of 3.41% is fine compared to the rest of the industry. ALPAT outperforms 77.22% of its industry peers.
Industry RankSector Rank
ROA 2.04%
ROE 3.41%
ROIC N/A
ROA(3y)1.24%
ROA(5y)-1.48%
ROE(3y)2.01%
ROE(5y)-3.12%
ROIC(3y)N/A
ROIC(5y)N/A
ALPAT.PA Yearly ROA, ROE, ROICALPAT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10 -15

1.3 Margins

  • ALPAT's Profit Margin of 33.77% is amongst the best of the industry. ALPAT outperforms 94.94% of its industry peers.
  • ALPAT's Gross Margin of 144.97% is amongst the best of the industry. ALPAT outperforms 100.00% of its industry peers.
  • ALPAT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 33.77%
GM 144.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
ALPAT.PA Yearly Profit, Operating, Gross MarginsALPAT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ALPAT.PA Health Analysis

2.1 Basic Checks

  • ALPAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALPAT has been increased compared to 1 year ago.
  • ALPAT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ALPAT has an improved debt to assets ratio.
ALPAT.PA Yearly Shares OutstandingALPAT.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
ALPAT.PA Yearly Total Debt VS Total AssetsALPAT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of 0.49, we must say that ALPAT is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.49, ALPAT is in line with its industry, outperforming 50.63% of the companies in the same industry.
  • ALPAT has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
  • ALPAT has a Debt to Equity ratio (0.40) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 0.49
ROIC/WACCN/A
WACC6.7%
ALPAT.PA Yearly LT Debt VS Equity VS FCFALPAT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

2.3 Liquidity

  • ALPAT has a Current Ratio of 0.89. This is a bad value and indicates that ALPAT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of ALPAT (0.89) is worse than 72.15% of its industry peers.
  • A Quick Ratio of 0.32 indicates that ALPAT may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.32, ALPAT is doing worse than 91.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.32
ALPAT.PA Yearly Current Assets VS Current LiabilitesALPAT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALPAT.PA Growth Analysis

3.1 Past

  • The earnings per share for ALPAT have decreased strongly by -72.16% in the last year.
  • ALPAT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.80%.
  • ALPAT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.44% yearly.
EPS 1Y (TTM)-72.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.9%
Revenue 1Y (TTM)-62.8%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-86.41%

3.2 Future

  • ALPAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.40% yearly.
  • ALPAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.88% yearly.
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALPAT.PA Yearly Revenue VS EstimatesALPAT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1M 2M 3M 4M
ALPAT.PA Yearly EPS VS EstimatesALPAT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

5

4. ALPAT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 28.21 indicates a quite expensive valuation of ALPAT.
  • Based on the Price/Earnings ratio, ALPAT is valued cheaply inside the industry as 81.01% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.91. ALPAT is around the same levels.
  • A Price/Forward Earnings ratio of 13.70 indicates a correct valuation of ALPAT.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALPAT indicates a rather cheap valuation: ALPAT is cheaper than 96.20% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.69. ALPAT is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 28.21
Fwd PE 13.7
ALPAT.PA Price Earnings VS Forward Price EarningsALPAT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALPAT is valued a bit cheaper than the industry average as 77.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 53.03
ALPAT.PA Per share dataALPAT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • ALPAT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ALPAT's earnings are expected to grow with 68.40% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y68.4%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALPAT.PA Dividend Analysis

5.1 Amount

  • No dividends for ALPAT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALPAT.PA Fundamentals: All Metrics, Ratios and Statistics

PLANT ADVANCED TECHNOLOGIES

EPA:ALPAT (4/8/2026, 7:00:00 PM)

7.9

+0.1 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)04-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners33.32%
Ins Owner ChangeN/A
Market Cap8.93M
Revenue(TTM)941.80K
Net Income(TTM)318.00K
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 28.21
Fwd PE 13.7
P/S 9.48
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 1.56
EV/EBITDA 53.03
EPS(TTM)0.28
EY3.54%
EPS(NY)0.58
Fwd EY7.3%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.83
BVpS8.26
TBVpS5.06
PEG (NY)0.29
PEG (5Y)N/A
Graham Number7.22
Profitability
Industry RankSector Rank
ROA 2.04%
ROE 3.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 33.77%
GM 144.97%
FCFM N/A
ROA(3y)1.24%
ROA(5y)-1.48%
ROE(3y)2.01%
ROE(5y)-3.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.17%
GM growth 5Y-4.76%
F-ScoreN/A
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA 15.75
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.32
Altman-Z 0.49
F-ScoreN/A
WACC6.7%
ROIC/WACCN/A
Cap/Depr(3y)108.48%
Cap/Depr(5y)137.54%
Cap/Sales(3y)44.29%
Cap/Sales(5y)66.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.9%
EPS Next Y97.01%
EPS Next 2Y68.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-62.8%
Revenue growth 3Y-5.79%
Revenue growth 5Y10.44%
Sales Q2Q%-86.41%
Revenue Next Year13.04%
Revenue Next 2Y31.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-189.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.11%
OCF growth 3YN/A
OCF growth 5YN/A

PLANT ADVANCED TECHNOLOGIES / ALPAT.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PLANT ADVANCED TECHNOLOGIES?

ChartMill assigns a fundamental rating of 3 / 10 to ALPAT.PA.


What is the valuation status for ALPAT stock?

ChartMill assigns a valuation rating of 5 / 10 to PLANT ADVANCED TECHNOLOGIES (ALPAT.PA). This can be considered as Fairly Valued.


What is the profitability of ALPAT stock?

PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) has a profitability rating of 3 / 10.


How financially healthy is PLANT ADVANCED TECHNOLOGIES?

The financial health rating of PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) is 1 / 10.


Can you provide the expected EPS growth for ALPAT stock?

The Earnings per Share (EPS) of PLANT ADVANCED TECHNOLOGIES (ALPAT.PA) is expected to grow by 97.01% in the next year.